KVYO:NYSEKlaviyo, Inc. Series A Analysis
Data as of 2026-06-20 - not real-time
$13.25
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Klaviyo, Inc. (KVYO) trades at roughly $13.25, which is less than half of its DCF‑derived fair value of $31.96, implying a potential upside of over 120% and an analyst consensus of strong buy with a median target near $30. The company is posting robust top‑line momentum, with revenue up 28% YoY and a gross margin of 74.5%, yet profitability remains elusive – operating margin is near breakeven and net profit margin is slightly negative, reflected in a trailing EPS of –$0.03. Cash on hand exceeds $984 million while debt is modest at $117 million, giving KVYO a strong liquidity cushion despite a high debt‑to‑equity ratio driven by negative equity.
Technical indicators are currently bearish: the price sits below the 20‑day (≈$14.95), 50‑day (≈$16.67) and 200‑day (≈$23.40) moving averages, RSI is at 34.8 suggesting oversold conditions, and the MACD histogram is negative. Volume is trending down, volatility is elevated at ~68% over 30 days, and the stock is hovering near its support level of $13.10 with resistance around $18.55. Recent news of a short‑interest driven rally to $18.36 and analyst coverage highlights short‑term buying interest, but the broader technical picture and earnings challenges keep the near‑term outlook cautious.
Technical indicators are currently bearish: the price sits below the 20‑day (≈$14.95), 50‑day (≈$16.67) and 200‑day (≈$23.40) moving averages, RSI is at 34.8 suggesting oversold conditions, and the MACD histogram is negative. Volume is trending down, volatility is elevated at ~68% over 30 days, and the stock is hovering near its support level of $13.10 with resistance around $18.55. Recent news of a short‑interest driven rally to $18.36 and analyst coverage highlights short‑term buying interest, but the broader technical picture and earnings challenges keep the near‑term outlook cautious.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish moving‑average alignment
- High 30‑day volatility and decreasing volume
- Recent short‑interest rally may be short‑lived
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside (>120%) versus DCF fair value
- Strong revenue growth and high gross margin
- Positive forward EPS and ample cash reserves
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strategic AI‑driven product suite positioning in the B2C CRM market
- Undervalued relative to industry PE and DCF expectations
- Long‑term cash generation potential despite current losses
Key Metrics & Analysis
Financial Health
Revenue Growth27.90%
Profit Margin-0.66%
P/E Ratio12.8
ROE-0.78%
ROA-1.66%
Debt/Equity10.16
P/B Ratio3.5
Op. Cash Flow$237.9M
Free Cash Flow$241.5M
Industry P/E38.1
Technical Analysis
TrendBearish
RSI34.8
Support$13.10
Resistance$18.55
MA 20$14.95
MA 50$16.67
MA 200$23.40
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Fair Value$31.96
Target Price$29.23
Upside/Downside120.58%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.84
Volatility67.62%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.